ITCI vs. VIE, RARX, AIMT, KURA, IRWD, ALNY, TEVA, GMAB, RPRX, and BMRN
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viela Bio (VIE), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Kura Oncology (KURA), Ironwood Pharmaceuticals (IRWD), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Intra-Cellular Therapies (NASDAQ:ITCI) and Viela Bio (NASDAQ:VIE) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Intra-Cellular Therapies has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.
Intra-Cellular Therapies presently has a consensus target price of $94.83, indicating a potential upside of 17.97%. Given Intra-Cellular Therapies' higher possible upside, equities research analysts clearly believe Intra-Cellular Therapies is more favorable than Viela Bio.
Viela Bio has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Intra-Cellular Therapies had 12 more articles in the media than Viela Bio. MarketBeat recorded 12 mentions for Intra-Cellular Therapies and 0 mentions for Viela Bio. Intra-Cellular Therapies' average media sentiment score of 0.97 beat Viela Bio's score of 0.00 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.
92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 47.0% of Viela Bio shares are owned by institutional investors. 3.4% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 31.5% of Viela Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Intra-Cellular Therapies received 509 more outperform votes than Viela Bio when rated by MarketBeat users. Likewise, 67.59% of users gave Intra-Cellular Therapies an outperform vote while only 40.00% of users gave Viela Bio an outperform vote.
Viela Bio has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -21.57%. Intra-Cellular Therapies' return on equity of -18.49% beat Viela Bio's return on equity.
Summary
Intra-Cellular Therapies beats Viela Bio on 12 of the 17 factors compared between the two stocks.
Get Intra-Cellular Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intra-Cellular Therapies Competitors List
Related Companies and Tools
